I. Udvaros

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

A. Johne, H. Scheible, O. von Richter, 2016, British journal of clinical pharmacology.

[PET scanning in head and neck cancer]

L. Trón, S. Szakáll, M. Kásler, 2001, Magyar onkologia.

OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA

B. Rojkovich, J. Holz, S. De Bruyn, 2013 .